Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $5.19 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.